Can a simple questionnaire predict psoriatic arthritis in psoriasis patients?

Psoriasis, a chronic inflammatory skin condition, affects approximately 2-3% of the global population. For up to 30% of these individuals, psoriatic arthritis (PsA) develops, a progressive inflammatory arthropathy that can lead to irreversible joint damage and significant functional impairment. The challenge for clinicians lies in identifying which psoriasis patients will progress to PsA, often before overt joint symptoms become apparent. Early intervention is paramount, but current screening methods can be inconsistent.¹

The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire designed to identify patients with psoriasis who have co-existing psoriatic arthritis. Researchers investigated the longitudinal performance of the PEST questionnaire in the prospective, observational, 5-year PURE registry. This registry enrolled patients from Canada and Latin America, providing a diverse cohort for evaluating the tool's utility over an extended period. The study aimed to understand how well PEST performs not just at a single point, but in tracking the development of PsA over time.¹

Evaluating the PEST Questionnaire's Predictive Power

Beecker, Albrecht, and Dei-Cas conducted a comprehensive analysis within the PURE registry, focusing on the PEST questionnaire's ability to identify PsA in psoriasis patients. The PURE registry, a prospective, observational study, followed patients for five years, collecting data on disease progression, treatment, and quality of life. This longitudinal design allowed for a robust evaluation of PEST's performance beyond cross-sectional assessments. The PEST questionnaire asks about joint pain, swelling, stiffness, and a history of PsA diagnosis, with each 'yes' answer contributing to a score. A score of 3 or more typically indicates a higher likelihood of PsA.¹

The investigators tracked changes in PEST scores over the five-year observation period and correlated these with confirmed PsA diagnoses. While specific sensitivity and specificity values for the PURE registry analysis were not detailed in the abstract, the study's focus on longitudinal performance implies an assessment of its predictive value for new PsA onset. The PEST tool's simplicity makes it an attractive option for routine clinical screening, particularly in primary care or dermatology settings where PsA expertise may be limited. Its effectiveness in a real-world, diverse population like that of the PURE registry is crucial for its broader adoption.¹

The CALLY Index and Disease Activity in PsA

Beyond screening for PsA, assessing disease activity is vital for guiding treatment decisions and monitoring therapeutic response. Yıldırım and Limon explored the CALLY index, a novel measure, and its association with disease activity in psoriatic arthritis. Their retrospective cohort study aimed to determine if lower CALLY index values correlated with higher disease activity in PsA patients. The CALLY index, while not explicitly detailed in the abstract, represents a composite measure likely incorporating various clinical and patient-reported outcomes to quantify disease severity.²

The study found that lower CALLY index values were associated with higher disease activity in psoriatic arthritis. This inverse relationship suggests the CALLY index could serve as a valuable tool for clinicians to objectively track PsA severity. For instance, a patient presenting with a CALLY index score of less than 10 might have significantly higher disease activity compared to a patient with a score of greater than 20, necessitating a more aggressive treatment approach. This finding offers a quantifiable metric to complement subjective patient reports and clinical examination, potentially leading to more precise and timely adjustments in therapy.²

The utility of such an index extends to clinical trials, where standardized measures of disease activity are essential for evaluating drug efficacy. In routine practice, it could help identify patients who are not responding adequately to current treatment, prompting a re-evaluation of their therapeutic regimen. The retrospective nature of this study, however, means it cannot establish causality, only association. Future prospective studies would be needed to confirm the CALLY index's predictive power for treatment response or disease progression.²

Systemic Immune-Inflammation Index as a Predictive Biomarker

Trovato, La Marca, and Simonini investigated the Systemic Immune-Inflammation Index (SII) as a potential predictive biomarker for therapeutic response in psoriasis. While their study focused on psoriasis rather than PsA directly, the systemic inflammatory nature of both conditions means insights into psoriasis biomarkers can often inform PsA management. The SII is calculated from peripheral blood cell counts, specifically platelets, neutrophils, and lymphocytes, reflecting the balance between pro-inflammatory and anti-inflammatory processes.³

Their retrospective comparative analysis evaluated the SII's predictive value across different classes of biologic agents: anti-TNF, anti-IL-17, and anti-IL-23 agents. These biologics are mainstays in the treatment of both moderate-to-severe psoriasis and psoriatic arthritis. The study aimed to determine if baseline SII values could predict which patients would respond favorably to a particular biologic therapy. Identifying such biomarkers could personalize treatment, avoiding costly and ineffective therapies for non-responders.³

The researchers compared SII values in responders versus non-responders to each biologic class. While specific numerical outcomes (e.g., hazard ratios, p-values) were not provided in the abstract, the study's objective was to establish the SII as a predictive biomarker. If a particular SII range consistently predicted a better response to, say, an anti-IL-17 agent, clinicians could use this information to guide their initial choice of biologic. This would move beyond the current trial-and-error approach, which can delay effective treatment and increase patient burden.³

The implications for PsA are clear: if SII can predict response in psoriasis, it may also predict response in PsA, given the shared inflammatory pathways. This could be particularly useful in patients with both skin and joint involvement, allowing for a more integrated treatment strategy. The retrospective design, however, means that confounding factors might influence the observed associations. Prospective studies with larger cohorts and specific PsA endpoints would be necessary to validate SII as a predictive biomarker in psA.³

Integrating Screening and Biomarkers for PsA Prediction

The PURE registry's longitudinal data on the PEST questionnaire offers a practical, low-cost method for ongoing PsA screening in dermatology clinics. A simple, validated questionnaire can empower general practitioners and dermatologists to identify patients who warrant further rheumatological evaluation. This proactive approach can significantly reduce the diagnostic delay for PsA, which often spans several years from symptom onset. Reducing this delay is critical, as early treatment initiation in PsA is associated with better long-term outcomes, including less joint damage and improved physical function.¹

But the PEST questionnaire is not a diagnostic tool; it is a screening instrument. A positive PEST score necessitates referral to a rheumatologist for definitive diagnosis. The challenge remains in ensuring these referrals are timely and that rheumatology services have the capacity to manage increased patient volumes. The Oxford Handbook of Rheumatology provides a concise reference for managing such complex cases.

The CALLY index, as explored by Yıldırım and Limon, provides a quantitative measure of disease activity. This is important because PsA can manifest heterogeneously, with varying degrees of skin, joint, enthesial, and dactylitic involvement. A composite index helps standardize assessment and track treatment efficacy. The association of lower CALLY values with higher disease activity offers a clear, actionable metric for clinicians. Integrating such an index into electronic health records could facilitate automated tracking and flagging of patients whose disease activity is worsening, prompting timely intervention.²

The potential of the Systemic Immune-Inflammation Index (SII) as a predictive biomarker, as investigated by Trovato and colleagues, adds another layer of sophistication. If SII can predict response to specific biologics in psoriasis, it opens the door to precision medicine in PsA. Instead of cycling through multiple expensive biologics, clinicians could potentially select the most effective agent upfront based on a simple blood test. This would not only improve patient outcomes but also reduce healthcare costs associated with ineffective treatments. However, the SII is a non-specific inflammatory marker, and its predictive power needs to be rigorously validated in dedicated PsA cohorts.³

Where the Current Data Falls Short

While these studies offer valuable insights, several limitations warrant consideration. The PURE registry analysis of PEST, while longitudinal, does not provide specific performance metrics such as sensitivity, specificity, or positive/negative predictive values in its abstract. Without these numbers, the true clinical utility for predicting new PsA onset remains somewhat opaque. Clinicians need concrete data to assess the reliability of a screening tool in their practice.¹

The CALLY index study was retrospective, meaning it identified associations but could not establish causation. Furthermore, the abstract did not detail the components of the CALLY index, making it difficult to fully understand its clinical relevance or replicate its use. A lack of transparency in index composition can hinder adoption. The SII study also suffered from a retrospective design, and its focus on psoriasis means direct extrapolation to PsA requires further validation. Inflammatory markers can be influenced by numerous factors, and the SII's specificity for predicting biologic response in PsA needs dedicated prospective trials.^2,3

None of these papers provided a comprehensive model integrating all three elements (PEST, CALLY, SII) to predict PsA development or treatment response. Such a multi-marker approach would likely offer superior predictive power compared to any single tool. The absence of head-to-head comparisons between different screening or prognostic tools also leaves clinicians without clear guidance on which tool is superior in specific clinical contexts. The next step for the field is to develop and validate integrated predictive models that combine clinical screening with robust biomarkers to truly personalize PsA management.